{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,25]],"date-time":"2026-01-25T00:29:34Z","timestamp":1769300974347,"version":"3.49.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T00:00:00Z","timestamp":1725840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T00:00:00Z","timestamp":1725840000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-024-01300-w","type":"journal-article","created":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T07:02:11Z","timestamp":1725865331000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Adverse drug reactions and drug-related problems with supportive care medications among the oncological population"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-7340-5086","authenticated-orcid":false,"given":"Batoul Barari","family":"Tajani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Maheswari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vinayak V.","family":"Maka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anjana S.","family":"Nair","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,9,9]]},"reference":[{"key":"1300_CR1","doi-asserted-by":"publisher","DOI":"10.9734\/jpri\/2021\/v33i59a34321","author":"KO Ahmed","year":"2021","unstructured":"Ahmed KO, Muddather HF, Yousef BA. Pharmaceutical Care Network Europe (PCNE) drug-related problems classification version 9.1: first implementation in Sudan. J Pharm Res Int. 2021. https:\/\/doi.org\/10.9734\/jpri\/2021\/v33i59a34321.","journal-title":"J Pharm Res Int"},{"key":"1300_CR2","doi-asserted-by":"publisher","first-page":"4874","DOI":"10.21608\/EJHM.2022.260758","volume":"89","author":"S Nabil","year":"2022","unstructured":"Nabil S, El-Shitany NA, Shawki MA, et al. A pharmaceutical care plan to minimize the incidence of potential drug-related problems in cancer patients. Egypt J Hosp Med. 2022;89:4874\u201380. https:\/\/doi.org\/10.21608\/EJHM.2022.260758.","journal-title":"Egypt J Hosp Med"},{"key":"1300_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-020-80560-2","volume":"11","author":"N Garin","year":"2021","unstructured":"Garin N, Sole N, Lucas B, et al. Drug related problems in clinical practice: a cross-sectional study on their prevalence, risk factors and associated pharmaceutical interventions. Sci Rep. 2021;11:1\u201311. https:\/\/doi.org\/10.1038\/s41598-020-80560-2.","journal-title":"Sci Rep"},{"key":"1300_CR4","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/6785835","author":"MB Yismaw","year":"2020","unstructured":"Yismaw MB, Adam H, Engidawork E. Identification and resolution of drug-related problems among childhood cancer patients in Ethiopia. J Oncol. 2020. https:\/\/doi.org\/10.1155\/2020\/6785835.","journal-title":"J Oncol"},{"key":"1300_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.vhri.2017.03.003","volume":"14","author":"GRM de Freitas","year":"2017","unstructured":"de Freitas GRM, Tramontina MY, Balbinotto G, et al. Economic impact of emergency visits due to drug-related morbidity on a Brazilian Hospital. Value Heal Reg Issues. 2017;14:1\u20138. https:\/\/doi.org\/10.1016\/j.vhri.2017.03.003.","journal-title":"Value Heal Reg Issues"},{"issue":"3","key":"1300_CR6","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1007\/s00520-019-04885-z","volume":"28","author":"M Nishii","year":"2020","unstructured":"Nishii M, Soutome S, Kawakita A, et al. Factors associated with severe oral mucositis and candidiasis in patients undergoing radiotherapy for oral and oropharyngeal carcinomas: a retrospective multicenter study of 326 patients. Support Care Cancer. 2020;28(3):1069\u201375.","journal-title":"Support Care Cancer"},{"issue":"8","key":"1300_CR7","first-page":"2019","volume":"18","author":"A Shankar","year":"2017","unstructured":"Shankar A, Roy S, Bhandari M, et al. Current trends in management of oral mucositis in cancer treatment. Asian Pac J Cancer Prev. 2017;18(8):2019\u201326.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"1","key":"1300_CR8","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1186\/s12885-021-08793-6","volume":"21","author":"Y Kawashita","year":"2021","unstructured":"Kawashita Y, Kitamura M, Soutome S, et al. Association of neutrophil-to-lymphocyte ratio with severe radiationinduced mucositis in pharyngeal or laryngeal cancer patients: a retrospective study. BMC Cancer. 2021;21(1):1064.","journal-title":"BMC Cancer"},{"issue":"10","key":"1300_CR9","doi-asserted-by":"publisher","first-page":"2661","DOI":"10.3390\/biomedicines10102661","volume":"10","author":"Y Kawashita","year":"2022","unstructured":"Kawashita Y, Soutome S, Umeda M, Saito T. Predictive risk factors associated with severe radiation-induced mucositis pharyngeal or oropharyngeal cancer patients: a retrospective study. Biomedicines. 2022;10(10):2661.","journal-title":"Biomedicines"},{"issue":"3","key":"1300_CR10","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.ejon.2014.12.001","volume":"19","author":"SC Chen","year":"2015","unstructured":"Chen SC, Lai YH, Huang BS, Lin CY, Fan KH, Chang JT. Changes and predictors of radiation-induced oral mucositis in patients with oral cavity cancer during active treatment. Eur J Oncol Nurs. 2015;19(3):214\u20139.","journal-title":"Eur J Oncol Nurs"},{"key":"1300_CR11","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.critrevonc.2016.01.010","volume":"100","author":"V De Sanctis","year":"2016","unstructured":"De Sanctis V, Bossi P, Sanguineti G, et al. Mucositis in head and neck cancer patients treated with radiotherapy and systemic therapies: literature review and consensus statements. Crit Rev Oncol Hematol. 2016;100:147\u201366.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"1300_CR12","doi-asserted-by":"publisher","first-page":"15898","DOI":"10.1038\/s41598-020-72592-5","volume":"10","author":"E Gebri","year":"2020","unstructured":"Gebri E, Kiss A, T\u00f3th F, Hortob\u00e1gyi T. Female sex as an independent prognostic factor in the development of oral mucositis during autologous peripheral stem cell transplantation. Sci Rep. 2020;10(1):15898.","journal-title":"Sci Rep"},{"issue":"1","key":"1300_CR13","doi-asserted-by":"publisher","first-page":"219","DOI":"10.3390\/curroncol30010017","volume":"30","author":"Z Liu","year":"2022","unstructured":"Liu Z, Huang L, Wang H, et al. Predicting nomogram for severe oral mucositis in patients with nasopharyngeal carcinoma during intensity-modulated radiation therapy: a retrospective cohort study. Curr Oncol. 2022;30(1):219\u201332.","journal-title":"Curr Oncol"},{"issue":"10","key":"1300_CR14","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1016\/j.oraloncology.2012.05.001","volume":"48","author":"MC Merlano","year":"2012","unstructured":"Merlano MC, Monteverde M, Colantonio I, et al. Impact of age on acute toxicity induced by bio- or chemo-radiotherapy in patients with head and neck cancer. Oral Oncol. 2012;48(10):1051\u20137.","journal-title":"Oral Oncol"},{"issue":"9","key":"1300_CR15","doi-asserted-by":"publisher","first-page":"4345","DOI":"10.1007\/s00520-019-05241-x","volume":"28","author":"K Morais-Faria","year":"2020","unstructured":"Morais-Faria K, Palmier NR, de Lima CJ, et al. Young head and neck cancer patients are at increased risk of developing oral mucositis and trismus. Support Care Cancer. 2020;28(9):4345\u201352.","journal-title":"Support Care Cancer"},{"issue":"50","key":"1300_CR16","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000008446","volume":"96","author":"Z Tao","year":"2017","unstructured":"Tao Z, Gao J, Qian L, et al. Factors associated with acute oral mucosal reaction induced by radiotherapy in head and neck squamous cell carcinoma: a retrospective single-center experience. Medicine. 2017;96(50): e8446.","journal-title":"Medicine"},{"issue":"9","key":"1300_CR17","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/j.oraloncology.2014.06.010","volume":"50","author":"M Vatca","year":"2014","unstructured":"Vatca M, Lucas JJ, Laudadio J, et al. Retrospective analysis of the impact of HPV status and smoking on mucositis in patients with oropharyngeal squamous cell carcinoma treated with concurrent chemotherapy and radiotherapy. Oral Oncol. 2014;50(9):869\u201376.","journal-title":"Oral Oncol"},{"key":"1300_CR18","first-page":"533","volume":"47","author":"C Hepler","year":"1990","unstructured":"Hepler C, Strand L. Opportunities and responsibilities in pharmaceutical care. Am J Hosp Pharm. 1990;47:533\u201343.","journal-title":"Am J Hosp Pharm"},{"key":"1300_CR19","doi-asserted-by":"publisher","first-page":"743138","DOI":"10.3389\/fpubh.2022.743138","volume":"3","author":"T Krustev","year":"2022","unstructured":"Krustev T, Milushewa P, Tachkov K. Impact of polypharmacy, drug-related problems, and potentially inappropriate medications in geriatric patients and its implications for bulgaria-narrative review and metanalysis. Front Public Health. 2022;3:743138.","journal-title":"Front Public Health"},{"key":"1300_CR20","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1007\/s11096-020-01150-w","volume":"43","author":"E Schindler","year":"2020","unstructured":"Schindler E, Richling I, Rose O, et al. Pharmaceutical Care Network Europe (PCNE) drug-related problem classification version 9.00: German translation and validation. Int J Clin Pharm. 2020;43:726\u201330.","journal-title":"Int J Clin Pharm"},{"key":"1300_CR21","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s11606-010-1256-6","volume":"25","author":"KM Gleason","year":"2010","unstructured":"Gleason KM. Results of the medications at transitions and clinical handofs (MATCH) study: an analysis of medication reconciliation errors and risk factors at hospital admission. J Gen Intern Med. 2010;25:441\u20137.","journal-title":"J Gen Intern Med"},{"key":"1300_CR22","doi-asserted-by":"publisher","first-page":"397","DOI":"10.7326\/0003-4819-158-5-201303051-00006","volume":"158","author":"JL Kwan","year":"2013","unstructured":"Kwan JL, Sampson LL, Shojania M, K G, et al. Medication reconciliation during transitions of care as a patient safety strategy. Ann Intern Med. 2013;158:397\u2013403.","journal-title":"Ann Intern Med"},{"key":"1300_CR23","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.sapharm.2017.07.009","volume":"14","author":"J Freyer","year":"2018","unstructured":"Freyer J. Drug-related problems in geriatric rehabilitation patients after discharge\u2014a prevalence analysis and clinical case scenario-based pilot study. Res Soc Adm Pharm. 2018;14:628\u201337.","journal-title":"Res Soc Adm Pharm"},{"key":"1300_CR24","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1111\/ijpp.12013","volume":"21","author":"K Maxwell","year":"2013","unstructured":"Maxwell K, Harrison J, Scahill S, Braund R, et al. Identifying drug-related problems during transition between secondary and primary care in New Zealand. Int J Pharm Pract. 2013;21:333\u20136.","journal-title":"Int J Pharm Pract"},{"key":"1300_CR25","doi-asserted-by":"publisher","first-page":"e006376","DOI":"10.1136\/bmjopen-2014-006376","volume":"5","author":"CP Kaufmann","year":"2015","unstructured":"Kaufmann CP, Stampfi D, Hersberger KE, Lampert ML, et al. Determination of risk factors for drug-related problems: a multidisciplinary triangulation process. BMJ Open. 2015;5:e006376\u2013e006376.","journal-title":"BMJ Open"},{"key":"1300_CR26","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.amjopharm.2010.04.002","volume":"8","author":"KT Unroe","year":"2010","unstructured":"Unroe KT. Inpatient medication reconciliation at admission and discharge: a retrospective cohort study of age and other risk factors for medication discrepancies. Am J Geriatr Pharmacother. 2010;8:115\u201326.","journal-title":"Am J Geriatr Pharmacother"},{"key":"1300_CR27","first-page":"5","volume":"10","author":"F Van Mil","year":"2005","unstructured":"Van Mil F. Drug-related problems: a cornerstone for pharmaceutical care. J Malta Coll Pharm Pract. 2005;10:5\u20138.","journal-title":"J Malta Coll Pharm Pract"},{"key":"1300_CR28","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1111\/j.1742-1241.2006.01130.x","volume":"61","author":"MM Ducharme","year":"2007","unstructured":"Ducharme MM, Boothby LA. Analysis of adverse drug reactions for preventability. Int J Clin Pract. 2007;61:157\u201361. https:\/\/doi.org\/10.1111\/j.1742-1241.2006.01130.x.","journal-title":"Int J Clin Pract"},{"key":"1300_CR29","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1002\/pds.1094","volume":"14","author":"TCG Egberts","year":"2005","unstructured":"Egberts TCG. Causal or casual? Pharmacoepidemiol Drug Saf. 2005;14:365\u20136. https:\/\/doi.org\/10.1002\/pds.1094.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1300_CR30","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/clpt.1981.154","volume":"30","author":"CA Naranjo","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239\u201345. https:\/\/doi.org\/10.1038\/clpt.1981.154.","journal-title":"Clin Pharmacol Ther"},{"key":"1300_CR31","first-page":"2229","volume":"49","author":"SC Hartwig","year":"1992","unstructured":"Hartwig SC, Siegel J, Schneider PJ. Pharmaceulicjl-carc index Notes. Am J Hosp Pharm. 1992;49:2229\u201332.","journal-title":"Am J Hosp Pharm"},{"key":"1300_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0199456","volume":"13","author":"S Iftikhar","year":"2018","unstructured":"Iftikhar S, Sarwar MR, Saqib A, Sarfraz M. Causality and preventability assessment of adverse drug reactions and adverse drug events of antibiotics among hospitalized patients: a multicenter, cross-sectional study in Lahore, Pakistan. PLoS ONE. 2018;13:1\u201318. https:\/\/doi.org\/10.1371\/journal.pone.0199456.","journal-title":"PLoS ONE"},{"key":"1300_CR33","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.yrtph.2010.12.007","volume":"59","author":"DA Volpe","year":"2011","unstructured":"Volpe DA. Uniform assessment and ranking of opioid Mu receptor binding constants for selected opioid drugs. Regul Toxicol Pharmacol. 2011;59:385\u201390.","journal-title":"Regul Toxicol Pharmacol"},{"key":"1300_CR34","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/S0009-9236(96)90211-8","volume":"60","author":"L Poulsen","year":"1996","unstructured":"Poulsen L, Arendt-Nielsen L, Br\u00f8sen K, et al. The hypoalgesic effect of tramadol in relation to CYP2D6. Clin Pharmacol Ther. 1996;60:636\u201344.","journal-title":"Clin Pharmacol Ther"},{"key":"1300_CR35","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/sj.clpt.6100152","volume":"82","author":"UM Stamer","year":"2007","unstructured":"Stamer UM, Musshoff F, Kobilay M, et al. Concentrations of tramadol and o-desmethyltramadol enantiomers in different CYP2D6 genotypes. Clin Pharmacol Ther. 2007;82:41\u20137.","journal-title":"Clin Pharmacol Ther"},{"key":"1300_CR36","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1016\/S0026-0495(03)00256-7","volume":"52","author":"J Borlak","year":"2003","unstructured":"Borlak J, Hermann R, Erb K, et al. A rapid and simple CYP2D6 genotyping assay\u2013case study with the analgetic tramadol. Metab Clin Exp. 2003;52:1439\u201343.","journal-title":"Metab Clin Exp"},{"key":"1300_CR37","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/clpt.2011.287","volume":"91","author":"KR Crews","year":"2012","unstructured":"Crews KR, Gaedigk A, Dunnenberger HM, et al. Clinical pharmacogenetics implementation consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype. Clin Pharmacol Ther. 2012;91:321\u20136. https:\/\/doi.org\/10.1038\/clpt.2011.287.","journal-title":"Clin Pharmacol Ther"},{"key":"1300_CR38","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1097\/00005792-200007000-00001","volume":"79","author":"PJ Mason","year":"2000","unstructured":"Mason PJ, Morris VA, Balcezak TJ. Serotonin syndrome presentation of 2 cases and review of the literature. Medicine. 2000;79:201\u20139. https:\/\/doi.org\/10.1097\/00005792-200007000-00001.","journal-title":"Medicine"},{"key":"1300_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/jcm6100092","volume":"6","author":"E Andr\u00e8s","year":"2017","unstructured":"Andr\u00e8s E, Mourot-Cottet R, Maloisel F, et al. History and outcome of febrile neutropenia outside the oncology setting: a retrospective study of 76 cases related to non-chemotherapy drugs. J Clin Med. 2017;6:1\u201312. https:\/\/doi.org\/10.3390\/jcm6100092.","journal-title":"J Clin Med"},{"key":"1300_CR40","volume-title":"Stockley\u2019s drug interactions","author":"K Baxter","year":"2008","unstructured":"Baxter K. Stockley\u2019s drug interactions. Chicago, London: Pharmaceutical Press; 2008."},{"key":"1300_CR41","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1007\/s00228-023-03612-2","volume":"80","author":"LMG Hulskotte","year":"2024","unstructured":"Hulskotte LMG, T\u00f6pfer W, Reyners AKL, et al. Drug-drug interaction perpetrators of oxycodone in patients with cancer: frequency and clinical relevance. Eur J Clin Pharmacol. 2024;80:455\u201364. https:\/\/doi.org\/10.1007\/s00228-023-03612-2.","journal-title":"Eur J Clin Pharmacol"},{"key":"1300_CR42","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s00520-014-2322-0","volume":"23","author":"J Lindsay","year":"2015","unstructured":"Lindsay J, Dooley M, Martin J, et al. The development and evaluation of an oncological palliative care deprescribing guideline: the \u2018OncPal deprescribing guideline.\u2019 Support Care Cancer. 2015;23:71\u20138. https:\/\/doi.org\/10.1007\/s00520-014-2322-0.","journal-title":"Support Care Cancer"},{"issue":"9","key":"1300_CR43","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1002\/cncr.30600","volume":"123","author":"EB Ludmir","year":"2017","unstructured":"Ludmir EB, Palta M, Willett CG, Czito BG. Total neoadjuvant therapy for rectal cancer: an emerging option. Cancer. 2017;123(9):1497\u2013506.","journal-title":"Cancer"},{"issue":"1","key":"1300_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/03009734.2016.1274806","volume":"122","author":"B Glimelius","year":"2017","unstructured":"Glimelius B. On a prolonged interval between rectal cancer (chemo)radiotherapy and surgery. Ups J Med Sci. 2017;122(1):1\u201310.","journal-title":"Ups J Med Sci"},{"issue":"7","key":"1300_CR45","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/S2468-1253(17)30074-2","volume":"2","author":"F Dossa","year":"2017","unstructured":"Dossa F, Chesney TR, Acuna SA, Baxter NN. A watch-and wait approach for locally advanced rectal cancer after a clinical complete response following neoadjuvant chemoradiation: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2017;2(7):501\u201313.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1300_CR46","doi-asserted-by":"publisher","first-page":"e968","DOI":"10.1634\/theoncologist.2018-0476","volume":"24","author":"AH Lavan","year":"2019","unstructured":"Lavan AH, et al. Adverse drug reactions in an oncological population: prevalence, predictability, and preventability. Oncologist. 2019;24:e968\u201377.","journal-title":"Oncologist"},{"key":"1300_CR47","doi-asserted-by":"publisher","first-page":"8S","DOI":"10.1111\/j.1532-5415.1991.tb05927.x","volume":"39","author":"LZ Rubenstein","year":"1991","unstructured":"Rubenstein LZ, Stuck AE, Siu AL, et al. Impacts of geriatric evaluation and management programs on defined outcomes: overview of the evidence. J Am Geriatr Soc. 1991;39:8S-16S.","journal-title":"J Am Geriatr Soc"},{"key":"1300_CR48","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1093\/jnci\/djs285","volume":"104","author":"MT Puts","year":"2012","unstructured":"Puts MT, Hardt J, Monette J, et al. Use of geriatric assessment for older adults in the oncology setting: a systematic review. J Natl Cancer Inst. 2012;104:1133\u201363.","journal-title":"J Natl Cancer Inst"},{"key":"1300_CR49","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.1200\/JCO.2018.78.8687","volume":"36","author":"SG Mohile","year":"2018","unstructured":"Mohile SG, Dale W, Somerfield MR, et al. Practical assessment and management of vulnerabilities in older patients receiving chemotherapy: ASCO guideline for geriatric oncology. J Clin Oncol. 2018;36:2326\u201347.","journal-title":"J Clin Oncol"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-024-01300-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-024-01300-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-024-01300-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T19:20:28Z","timestamp":1725909628000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-024-01300-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,9]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1300"],"URL":"https:\/\/doi.org\/10.1007\/s12672-024-01300-w","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,9]]},"assertion":[{"value":"23 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was authorized by the Ethics Committee of the M. S. Ramaiah Medical College Hospital (MSRMCH), Bengaluru, Karnataka, India, before to its start in December 2022. Prior to the start of the data collection procedure, the collecting form was accompanied with the consent form which was translated into Kannada language was signed by patient or family member. Ethics Committee, MS Ramaiah Medical College Hospital, Bangaluru, Karnataka, India is registered under DCGI (Drugs Controller General India) and Department of Health Services and works in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"416"}}